Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.

MLA

Burns, Jane C., et al. “Infliximab versus Second Intravenous Immunoglobulin for Treatment of Resistant Kawasaki Disease in the USA (KIDCARE): A Randomised, Multicentre Comparative Effectiveness Trial.” The Lancet. Child & Adolescent Health, vol. 5, no. 12, Dec. 2021, pp. 852–61. EBSCOhost, https://doi.org/10.1016/S2352-4642(21)00270-4.

APA

Burns, J. C., Roberts, S. C., Tremoulet, A. H., He, F., Printz, B. F., Ashouri, N., Jain, S. S., Michalik, D. E., Sharma, K., Truong, D. T., Wood, J. B., Kim, K. K., & Jain, S. (2021). Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. The Lancet. Child & Adolescent Health, 5(12), 852–861. https://doi.org/10.1016/S2352-4642(21)00270-4

Chicago

Burns, Jane C, Samantha C Roberts, Adriana H Tremoulet, Feng He, Beth F Printz, Negar Ashouri, Supriya S Jain, et al. 2021. “Infliximab versus Second Intravenous Immunoglobulin for Treatment of Resistant Kawasaki Disease in the USA (KIDCARE): A Randomised, Multicentre Comparative Effectiveness Trial.” The Lancet. Child & Adolescent Health 5 (12): 852–61. doi:10.1016/S2352-4642(21)00270-4.